Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
Balance Sheet
Inspect the capital base behind the business.
Assets
$330.18M
FY 2025 · Annual
-36.3% YoYLiabilities
$953.38M
FY 2025 · Annual
+0.0% YoYEquity
-$623.20M
FY 2025 · Annual
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 176.27M | 121.65M |
| Short-term Investments | 217.36M | 99.85M |
| Net Receivables | 308K | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 13.56M | 12.87M |
| Total Current Assets | 407.49M | 234.37M |
| Property, Plant & Equipment (Net) | 101.07M | 89.01M |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 9.7M | 6.81M |
| Total Non-current Assets | 110.77M | 95.82M |
| Total Assets | 518.26M | 330.18M |
| Account Payables | 5.67M | 3.84M |
| Short-term Debt | 0 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 42.43M | 21.19M |
| Other Current Liabilities | 15.78M | 16.43M |
| Total Current Liabilities | 86.63M | 82.2M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 15.17M | 4.51M |
| Other Non-current Liabilities | 791.29M | 813.15M |
| Total Non-current Liabilities | 866.72M | 871.18M |
| Total Liabilities | 953.35M | 953.38M |
| Common Stock | 50K | 50K |
| Retained Earnings | (473.14M) | (676.29M) |
| Accumulated OCI | 118K | 106K |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | (571K) | (7.23M) |
| Total Equity | (435.09M) | (623.2M) |
| Total Debt | 76.97M | 68.53M |
| Net Debt | (99.3M) | (53.12M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $160.6M |
| Short-term Investments | $356.1M |
| Other Current | $18.7M |
| Total Current Assets | $535.4M |
| PP&E (Net) | $85.6M |
| Other Non-current | $4.7M |
| Total Non-current Assets | $90.3M |
| Total Assets | $625.7M |
Analysis
Selected assets total $625.7M for Latest. The largest visible component is Short-term Investments at $356.1M, about 56.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 3, 2026 |
How much cash does GENB have?
Generate Biomedicines, Inc. (GENB) reported $121.65M in cash and equivalents in fiscal 2025.
How much debt does GENB carry?
Generate Biomedicines, Inc. (GENB) reported $68.53M of total debt, with net debt of -$53.12M.
Continue the stock analysis
Jump to another research area for this company.